ID30006A - Proses pembuatan garam mesilat trihidrat dari 1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol - Google Patents

Proses pembuatan garam mesilat trihidrat dari 1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol

Info

Publication number
ID30006A
ID30006A IDP20010342A ID20010342A ID30006A ID 30006 A ID30006 A ID 30006A ID P20010342 A IDP20010342 A ID P20010342A ID 20010342 A ID20010342 A ID 20010342A ID 30006 A ID30006 A ID 30006A
Authority
ID
Indonesia
Prior art keywords
trihidrate
phenilpiperidin
hydroxyphenyl
propanol
hydroxy
Prior art date
Application number
IDP20010342A
Other languages
English (en)
Indonesian (id)
Inventor
Joseph Philip Rainville
Terry Gene Sinay Jr
Stanley Walter Walinsky
Original Assignee
Pfizer Prod Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Prod Inc filed Critical Pfizer Prod Inc
Publication of ID30006A publication Critical patent/ID30006A/id

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/36—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D211/40—Oxygen atoms
    • C07D211/44—Oxygen atoms attached in position 4
    • C07D211/52—Oxygen atoms attached in position 4 having an aryl radical as the second substituent in position 4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D211/08—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms
    • C07D211/18—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D211/20—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms
    • C07D211/22—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon or substituted hydrocarbon radicals directly attached to ring carbon atoms with substituted hydrocarbon radicals attached to ring carbon atoms with hydrocarbon radicals, substituted by singly bound oxygen or sulphur atoms by oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Urology & Nephrology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • AIDS & HIV (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Endocrinology (AREA)
  • Communicable Diseases (AREA)
  • Hospice & Palliative Care (AREA)
  • Rheumatology (AREA)
  • Vascular Medicine (AREA)
IDP20010342A 2000-04-28 2001-04-26 Proses pembuatan garam mesilat trihidrat dari 1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol ID30006A (id)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US20067300P 2000-04-28 2000-04-28

Publications (1)

Publication Number Publication Date
ID30006A true ID30006A (id) 2001-11-01

Family

ID=22742684

Family Applications (1)

Application Number Title Priority Date Filing Date
IDP20010342A ID30006A (id) 2000-04-28 2001-04-26 Proses pembuatan garam mesilat trihidrat dari 1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol

Country Status (27)

Country Link
US (1) US6645986B2 (enExample)
EP (2) EP1477479A1 (enExample)
JP (2) JP3615496B2 (enExample)
KR (1) KR100442718B1 (enExample)
CN (2) CN1210262C (enExample)
AR (1) AR028376A1 (enExample)
AT (1) ATE277014T1 (enExample)
AU (1) AU781436B2 (enExample)
BR (1) BR0101630A (enExample)
CA (1) CA2345582C (enExample)
CZ (1) CZ20011471A3 (enExample)
DE (1) DE60105689T2 (enExample)
DK (1) DK1151995T3 (enExample)
ES (1) ES2227071T3 (enExample)
HK (1) HK1040246B (enExample)
HU (1) HUP0101723A3 (enExample)
ID (1) ID30006A (enExample)
IL (1) IL142705A0 (enExample)
IN (1) IN191027B (enExample)
PL (1) PL347298A1 (enExample)
PT (1) PT1151995E (enExample)
RU (1) RU2203888C2 (enExample)
SI (1) SI1151995T1 (enExample)
TR (1) TR200402696T4 (enExample)
TW (1) TW200505858A (enExample)
YU (1) YU27701A (enExample)
ZA (1) ZA200103320B (enExample)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60117556T2 (de) * 2000-06-21 2006-11-02 Bioarray Solutions Ltd. Multianalytische molekularanalyse durch verwendung anwendungsspezifischer zufallspartikelarrays
US6743921B2 (en) 2002-01-24 2004-06-01 Dsm Catalytica Pharmaceuticals, Inc. Process for the preparation of nonracemic syn-1-(4-hydroxy-phenyl)-2-(4-hydroxy-4-phenyl-piperidin-1-yl)-1-propanol compounds
CN1930304B (zh) * 2003-11-21 2016-01-06 Anp技术公司 不对称支化的聚合物缀合物和微阵列检测
US8563329B2 (en) 2005-05-02 2013-10-22 Anp Technologies, Inc. Polymer conjugate enhanced bioassays

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272160A (en) * 1989-05-17 1993-12-21 Pfizer Inc 2-piperidino-1-alkanol derivatives as antiischemic agents
BR9610766A (pt) * 1995-08-11 1999-07-13 Pfizer Triihdrato de metanossulfonato de (1s,2s)-1-(4-hidróxi-fenil)-2-(4-hidróxi-4-fenilpiperidin-1-il)-1-propanol

Also Published As

Publication number Publication date
KR20010098960A (ko) 2001-11-08
CZ20011471A3 (cs) 2002-02-13
PL347298A1 (en) 2001-11-05
US6645986B2 (en) 2003-11-11
HU0101723D0 (en) 2001-07-30
ZA200103320B (en) 2002-10-24
RU2203888C2 (ru) 2003-05-10
IN191027B (enExample) 2003-09-13
KR100442718B1 (ko) 2004-08-02
AR028376A1 (es) 2003-05-07
DE60105689T2 (de) 2005-11-10
HUP0101723A2 (hu) 2002-02-28
JP3615496B2 (ja) 2005-02-02
AU781436B2 (en) 2005-05-26
DK1151995T3 (da) 2004-12-13
ES2227071T3 (es) 2005-04-01
DE60105689D1 (de) 2004-10-28
IL142705A0 (en) 2002-03-10
HUP0101723A3 (en) 2003-03-28
SI1151995T1 (en) 2004-12-31
CN1210262C (zh) 2005-07-13
JP2004196823A (ja) 2004-07-15
TR200402696T4 (tr) 2004-11-22
AU3889601A (en) 2001-11-01
HK1040246B (zh) 2005-10-28
ATE277014T1 (de) 2004-10-15
CN1321638A (zh) 2001-11-14
EP1477479A1 (en) 2004-11-17
TW200505858A (en) 2005-02-16
US20020016465A1 (en) 2002-02-07
EP1151995B1 (en) 2004-09-22
CA2345582A1 (en) 2001-10-28
PT1151995E (pt) 2004-11-30
JP2001354651A (ja) 2001-12-25
YU27701A (sh) 2003-04-30
EP1151995A1 (en) 2001-11-07
BR0101630A (pt) 2001-12-04
HK1040246A1 (en) 2002-05-31
CA2345582C (en) 2006-05-30
CN1590373A (zh) 2005-03-09

Similar Documents

Publication Publication Date Title
NL1018400A1 (nl) Collageenbuizen voor zenuwregeneratie.
EE200200140A (et) Pteridinoonid kui kinaasi inhibiitorid
EP1620095A4 (en) HEMMER OF ACT ACTIVITY
IL173079A0 (en) Ppar active compounds
EP1898903A4 (en) HAMMER OF ACT ACTIVITY
FR2856982B1 (fr) Capsules de bouchage ameliorees et procede pour les fabriquer
FR2805296B1 (fr) Profile de structure, notamment pour cloisons
EP1304337A4 (en) PROCESS FOR THE PRODUCTION OF CELLULOSE
FI20011541A0 (fi) Menetelmä massan valmistamiseksi
EE200300294A (et) Sulfoonamiid-asendatud imidasotriasinoonide valmistamismeetod
EE200300266A (et) Asendatud 8-arüülkinoliinid kui fosfodiesteraas-4inhibiitorid
FI20001612L (fi) Menetelmä kuitulevyjen valmistamiseksi
MA26407A1 (fr) Procede de preparation de combretastatines
EP1276366A4 (en) Plant regeneration
ID30006A (id) Proses pembuatan garam mesilat trihidrat dari 1-(4-hidroksifenil)-2-(4-hidroksi-4-fenilpiperidin-1-il)-1-propanol
ID26278A (id) Proses pembuatan sertralina dari kiral tetralon
IT1316081B1 (it) Trappola per muridi
EE200200447A (et) Meetod tubaka täitevõime parandamiseks
EP1637883A4 (en) IMMUNOGROMATOGRAPHIC PROCESS
FI20020163A0 (fi) Menetelmä selluloosakarbamaatin valmistamiseksi
AU2002364774A1 (en) Ilk inhibitors for the treatment of renal disease
IL182353A0 (en) Methods using glycosaminoglycans for the treatment of kidney disease
ITRM20010309A0 (it) Procedimento per la produzione di composti perfluoro-organici mediante florurazione elettrochimica.
EE200200448A (et) Meetod tubaka täitevõime parandamiseks
AR028377A1 (es) Procedimiento para la preparacion de la sal mesilato trihidrato de 1-(4-hidroxifenil)-2-(4-hidroxi-4-fenilpiperidin-1-il)-1-propanol e intermedios utiles para dicha preparacion